Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 223

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Venetoclax Plus Azacitidine for Patients With Treatment-Naive High-Risk Myelodysplastic Syndromes

Jacqueline S. Garcia, Uwe Platzbecker, Olatoyosi Odenike, Shaun A Fleming, Chun Yew Fong, Uma Borate, Meagan A Jacoby, Daniel Nowak, Maria R Baer, Pierre Peterlin, Brenda Chyla, Huipei Wang, Grace Ku, David Hoffman, Jalaja Potluri, Guillermo Garcia-Manero

Blood blood.2024025464.

https://doi.org/10.1182/blood.2024025464

Published: 2024

Includes: Supplemental data

Journal Articles

A Phase 1, Open-Label, Dose Escalation and Dose Expansion, Multicenter Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Lomonitinib (ZE46-0134) in Adults with FLT3 -Mutated Relapsed or Refractory Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 2883.4.

https://doi.org/10.1182/blood-2024-208822

Published: 2024

Journal Articles

BRAF -Mutated Acute Myeloid Leukemia (AML) Represents a Prognostically Poor Subgroup Enriched for Myelodysplasia-Related Subtypes and Distinct from Other RAS Pathway Mutant AML

Blood (2024) 144 (Supplement 1): 2921.

https://doi.org/10.1182/blood-2024-210110

Published: 2024

Journal Articles

Quality-Adjusted Time without Symptoms of Disease or Toxicity (Q-TWiST) of Ponatinib Versus Imatinib, Administered in Combination with Reduced-Intensity Chemotherapy, in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Ajibade Ashaye, Ling Shi, Ibrahim Aldoss, Pau Montesinos, Pankit Vachhani, Cristina Papayannidis, Jessica T. Leonard, Maria R. Baer, Josep-Maria Ribera, James McCloskey, JianXiang Wang, Sujun Gao, Deepali Rane, Shien Guo

Blood (2024) 144 (Supplement 1): 2825.

https://doi.org/10.1182/blood-2024-208755

Published: 2024

Journal Articles

Ponatinib Monotherapy after Combination with Chemotherapy in Patients with Newly Diagnosed Ph+ ALL: Post Hoc Subgroup Analysis of the Phase 3 Phallcon Study

Blood (2024) 144 (Supplement 1): 2821.

https://doi.org/10.1182/blood-2024-208504

Published: 2024

Journal Articles

Combination of Olutasidenib and Azacitidine Induces Durable Complete Remissions in m IDH1 Acute Myeloid Leukemia: A Multicohort Open-Label Phase 1/2 Trial

Jorge E. Cortes, Gail J. Roboz, Justin M. Watts, Maria R. Baer, Brian A. Jonas, Gary J. Schiller, Karen Yee, Brent Ferrell, Jay Yang, Eunice S. Wang, William Blum, Alice Mims

Blood (2024) 144 (Supplement 1): 2886.

https://doi.org/10.1182/blood-2024-201710

Published: 2024

Journal Articles

Demographics, Characteristics, Survival and Outcomes in Older, Untreated, Acute Myeloid Leukemia Patients with NPM1 Mutations or KMT2A rearrangements from the Beat AML Master Clinical Trial

Blood (2024) 144 (Supplement 1): 1564.

https://doi.org/10.1182/blood-2024-211261

Published: 2024

Journal Articles

Olverembatinib (HQP1351) Overcomes Resistance/Intolerance to Asciminib and Ponatinib in Patients (pts) with Heavily Pretreated Chronic-Phase Chronic Myeloid Leukemia (CP-CML): A 1.5-Year Follow-up Update with Comprehensive Exposure-Response (E-R) Analyses

Blood (2024) 144 (Supplement 1): 3151.

https://doi.org/10.1182/blood-2024-207139

Published: 2024

Journal Articles

Lower Emergency Severity Index Assignment Results in Faster Time to First Analgesia in Patients with Sickle Cell Disease

Abdulaziz Abu Haimed, Drupad Patel, Octavia Clopton, Maria R. Baer, Benoit Stryckman, Richard Gentry Wilkerson, Jennie Law

Blood (2024) 144 (Supplement 1): 3618.

https://doi.org/10.1182/blood-2024-199851

Published: 2024

Journal Articles

Impact of Socioeconomic Factors on Access to and Outcomes of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Acute Myeloid Leukemia (AML): A Multi-Center Observational Study

Blood (2024) 144 (Supplement 1): 6.

https://doi.org/10.1182/blood-2024-202664

Published: 2024

Journal Articles

A Randomized Phase 2 Trial of 28-Day (Arm A) Versus 14-Day (Arm B) Schedule of Venetoclax + Azacitidine in Newly Diagnosed Acute Myeloid Leukemia Patients ≥ 60 Years

Blood (2024) 144 (Supplement 1): 2907.2.

https://doi.org/10.1182/blood-2024-210967

Published: 2024

Journal Articles

Olutasidenib Alone or in Combination with Azacitidine in Patients with m IDH1 Myelodysplastic Syndromes/Neoplasms: Final 5-Year Data

Jorge E. Cortes, Justin M. Watts, Eunice S. Wang, Jay Yang, Shira N. Dinner, Maria R. Baer, Gail J. Roboz, William B. Donnellan

Blood (2024) 144 (Supplement 1): 4600.

https://doi.org/10.1182/blood-2024-204039

Published: 2024

Journal Articles

IDH2 Mutation Is Associated with Favorable Outcome Among Older Adults with Newly Diagnosed Acute Myeloid Leukemia Treated with Lower-Intensity Therapy

Blood (2024) 144 (Supplement 1): 4325.

https://doi.org/10.1182/blood-2024-202596

Published: 2024

Journal Articles

Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age

Blood (2024) 144 (Supplement 1): 4324.

https://doi.org/10.1182/blood-2024-211178

Published: 2024

Journal Articles

A phase 1 study of the amino acid modulator pegcrisantaspase and venetoclax for relapsed/refractory acute myeloid leukemia

Yuchen Liu, Dominique R Bollino, Osman M Bah, Erin T Strovel, Tien Van Le, Jinoos Zarrabi, Sunita Philip, Rena G Lapidus, Maria R Baer, Sandrine Niyongere, Vu H. Duong, Christine C Dougherty, Jan Hendrik Beumer, Katherine D Caprinolo, Farin Kamangar, Ashkan Emadi

Blood blood.2024024837.

https://doi.org/10.1182/blood.2024024837

Published: 2024

Includes: Supplemental data

Journal Articles

Olutasidenib for the Treatment of mIDH1 Acute Myeloid Leukemia in Patients Relapsed or Refractory to Hematopoietic Stem Cell Transplant, Prior mIDH1 Inhibitor, or Venetoclax

Jorge Cortes, Joseph Jurcic, Maria R. Baer, William Blum, P. Brent Ferrell, Jr., Brian A. Jonas, Sangmin Lee, Alice Mims, Shyam Ajay Patel, Gary J. Schiller, Jay Yang, Justin M. Watts

Blood (2023) 142 (Supplement 1): 2888.

https://doi.org/10.1182/blood-2023-187861

Published: 2023

Journal Articles

Ponatinib Versus Imatinib in Patients with Newly Diagnosed Ph+ ALL: Subgroup Analysis of the Phase 3 Phallcon Study

Blood (2023) 142 (Supplement 1): 2871.

https://doi.org/10.1182/blood-2023-179537

Published: 2023

Journal Articles

Overcoming Venetoclax (Ven) Resistance through Glutamine (Gln) Depletion: Final Analysis of the Phase 1 Trial of Ven and Pegcrisantaspase (PegC) Combination in Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML)

Yuchen Liu, Dominique Bollino, Osman M Bah, Erin T Strovel, Jinoos Zarrabi, Sunita Philip, Ezzat Mostafa, Rena G Lapidus, Maria R. Baer, Sandrine Niyongere, Vu H. Duong, Christine C Dougherty, Katherine Caprinolo, Ashkan Emadi

Blood (2023) 142 (Supplement 1): 60.

https://doi.org/10.1182/blood-2023-186244

Published: 2023

Journal Articles

Genomic Characterization of Newly Diagnosed Acute Myeloid Leukemia in Patients Age 60 Years and Older; A Report from the Beat AML Master Trial

Blood (2023) 142 (Supplement 1): 4296.

https://doi.org/10.1182/blood-2023-187044

Published: 2023

Journal Articles

A Randomized Phase 2 Trial of 28-Day (Arm A) Versus 14-Day (Arm B) Schedule of Venetoclax + Azacitidine in Newly Diagnosed Acute Myeloid Leukemia Patients ≥ 60 Years

Blood (2023) 142 (Supplement 1): 1535.

https://doi.org/10.1182/blood-2023-187383

Published: 2023

NARROW

Efficacy and Safety of Venetoclax Plus Azacitidine for Patients With Treatment-Naive High-Risk Myelodysplastic Syndromes

A Phase 1, Open-Label, Dose Escalation and Dose Expansion, Multicenter Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Lomonitinib (ZE46-0134) in Adults with FLT3 -Mutated Relapsed or Refractory Acute Myeloid Leukemia

BRAF -Mutated Acute Myeloid Leukemia (AML) Represents a Prognostically Poor Subgroup Enriched for Myelodysplasia-Related Subtypes and Distinct from Other RAS Pathway Mutant AML

Quality-Adjusted Time without Symptoms of Disease or Toxicity (Q-TWiST) of Ponatinib Versus Imatinib, Administered in Combination with Reduced-Intensity Chemotherapy, in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Ponatinib Monotherapy after Combination with Chemotherapy in Patients with Newly Diagnosed Ph+ ALL: Post Hoc Subgroup Analysis of the Phase 3 Phallcon Study

Combination of Olutasidenib and Azacitidine Induces Durable Complete Remissions in m IDH1 Acute Myeloid Leukemia: A Multicohort Open-Label Phase 1/2 Trial

Demographics, Characteristics, Survival and Outcomes in Older, Untreated, Acute Myeloid Leukemia Patients with NPM1 Mutations or KMT2A rearrangements from the Beat AML Master Clinical Trial

Olverembatinib (HQP1351) Overcomes Resistance/Intolerance to Asciminib and Ponatinib in Patients (pts) with Heavily Pretreated Chronic-Phase Chronic Myeloid Leukemia (CP-CML): A 1.5-Year Follow-up Update with Comprehensive Exposure-Response (E-R) Analyses

Lower Emergency Severity Index Assignment Results in Faster Time to First Analgesia in Patients with Sickle Cell Disease

Impact of Socioeconomic Factors on Access to and Outcomes of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Acute Myeloid Leukemia (AML): A Multi-Center Observational Study

A Randomized Phase 2 Trial of 28-Day (Arm A) Versus 14-Day (Arm B) Schedule of Venetoclax + Azacitidine in Newly Diagnosed Acute Myeloid Leukemia Patients ≥ 60 Years

Olutasidenib Alone or in Combination with Azacitidine in Patients with m IDH1 Myelodysplastic Syndromes/Neoplasms: Final 5-Year Data

IDH2 Mutation Is Associated with Favorable Outcome Among Older Adults with Newly Diagnosed Acute Myeloid Leukemia Treated with Lower-Intensity Therapy

Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age

A phase 1 study of the amino acid modulator pegcrisantaspase and venetoclax for relapsed/refractory acute myeloid leukemia

Olutasidenib for the Treatment of mIDH1 Acute Myeloid Leukemia in Patients Relapsed or Refractory to Hematopoietic Stem Cell Transplant, Prior mIDH1 Inhibitor, or Venetoclax

Ponatinib Versus Imatinib in Patients with Newly Diagnosed Ph+ ALL: Subgroup Analysis of the Phase 3 Phallcon Study

Overcoming Venetoclax (Ven) Resistance through Glutamine (Gln) Depletion: Final Analysis of the Phase 1 Trial of Ven and Pegcrisantaspase (PegC) Combination in Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML)

Genomic Characterization of Newly Diagnosed Acute Myeloid Leukemia in Patients Age 60 Years and Older; A Report from the Beat AML Master Trial

A Randomized Phase 2 Trial of 28-Day (Arm A) Versus 14-Day (Arm B) Schedule of Venetoclax + Azacitidine in Newly Diagnosed Acute Myeloid Leukemia Patients ≥ 60 Years

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only